All In Biotech

Drug Trial Radar · NCT05565378

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

351

Actual

Start

Oct 14, 2022

Primary completion

Oct 26, 2026

Study completion Dec 6, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
iTeos Therapeutics
First posted
Oct 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

  • PembrolizumabDrug

    Pembrolizumab will be administered.

  • DostarlimabDrug

    Dostarlimab will be administered

  • BelrestotugDrug

    Belrestotug will be administered.

  • NelistotugDrug

    Nelistotug will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 228 weeks
  2. Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuationTime frame: Up to 228 weeks

Locations

99 sites in 22 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Chattanooga, Tennessee

  • GSK Investigational Site

    Morgantown, West Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Cipoletti Rio Negro, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Florida, Argentina

  • GSK Investigational Site

    Mar del Plata, Argentina

  • GSK Investigational Site

    San Juan, Argentina

  • GSK Investigational Site

    Santa Fe, Argentina

  • GSK Investigational Site

    Wilrijk, Belgium

  • GSK Investigational Site

    Barretos, Brazil

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vitória, Brazil

  • GSK Investigational Site

    Oulu, Finland

  • GSK Investigational Site

    Tampere, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Vaasa, Finland

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Quimper, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Heidelberg, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Großhansdorf, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Jena, Thuringia, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Pylaia Thessaloniki, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Athens, Attica, Greece

  • GSK Investigational Site

    Chaïdári, Attica, Greece

  • GSK Investigational Site

    Thessaloniki, Central Macedonia, Greece

  • GSK Investigational Site

    Larissa, Thessaly, Greece

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Gyöngyös, Hungary

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.